Previous 10 | Next 10 |
home / stock / gild / gild articles
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody prog...
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health ...
Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $79.44, after a 0.10% increase. Moreover, over the past ...
Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive ly...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.81% on an annualized basis producing an average annual return...
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of ad...
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's third-qua...
U.S. stocks are attempting to post the longest streak of consecutive positive sessions in over two years. As of midday trading in New York, both th...
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemothe...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...